CAS号:202825-46-5
品名:沙芬酰胺甲磺酸盐Safinamidemesylatesalt
中文别名:马波沙星,麻保沙星;
英文别名:SafinamideMesylate;(2S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide,methanesulfonicacid;(S)-2-(4-(3-fluorobenzyloxy)benzylamino)propanamide,methanesulfonate;(S)-(+)-2-[[4-(3-Fluorobenzoxy)benzyl]amino]propanamide;PNU-151774E,NW-1015;FCE-28073(R-isomer),PNU-151774E,NW-1015;(S)-2-[[4-[(3-Fluorobenzyl)oxy]benzyl]amino]propanamide;
分子式:C18H23FN2O5S
分子量:398.449
精确质量:398.131
Psa:127.1
MDL号:MFCD15145475
密度:
沸点:476.7ºC at 760 mmHg
闪点:242.1ºC
蒸汽压:2.98E-09mmHg at 25°C
海关编码:2924299090
信号词:Danger
危险性防范说明:P273; P280; P301 + P310; P305 + P351 + P338
危险标志:GHS05, GHS06, GHS09
危险性描述:H301; H318; H400
简介:Safinamide(INN;brandnameXadago,formerdevelopmentalcodenameEMD-1195686)isadrugindicatedforthetreatmentofParkinson'sdiseasewithmultiplemethodsofaction.In2007,aPhaseIIIclinicaltrialwasstarted.Itwasscheduledtorununtil2011.ThecompoundwasoriginallydiscoveredatFarmitalia-CarloErba,firstpublishedin1998anddevelopedbyNewronPharmaceuticals,whichsoldtherightstoMerck-Seronoin2006.InOctober2011Merck-SeronoannouncedthattheywouldgiveallrightstodevelopthecompoundbacktoNewron.